Alphabetical list:
A B C D E F G H I J K L M N O P R S T U V W X Y Q Z 1 2 3 4 5 6 7 8 9
News: November 21, 2009
Diabetes Drug Byetta Linked to Kidney Problems
November 21, 2009The FDA has received 78 reports of kidney problems related to Byetta, a drug by Amylin Pharmaceuticals and Eli-Lilly prescribed to treat type 2 diabetes. With the new findings, the drug's label will be updated to warn doctors and patients about this possible side effect.
Byetta (exenatide) was approved in 2005. It's known as an incretin mimetic, which copies the action of incretin GLP-1, a hormone that is released in response to eating food which causes insulin to be secreted from the pancreas to lower blood glucose. The drug is injected twice a day, similar to insulin.
The drug recently was approved as a stand-alone treatment for controlling blood sugar, whereas previously it was prescribed for patients also on other diabetic therapies.
The reports of kidney failure were filed between April 2005 and October 2008. Sixty-two of the cases were for acute renal failure and 16 were cases of renal insufficiency. Most of the problems occurred in patients with pre-existing kidney disease or one or more risk factors for developing kidney problems. 91% of the patients were hospitalized, 18 required dialysis, 2 had kidney transplants, and 4 died. 80% stopped taking Byetta, and half of those patients had improvements to kidney function after discontinuing the drug.
Between 2005 and 2008, approximately 7 million prescriptions were written for Byetta. The FDA said, "Therefore, the 78 reported cases of altered renal funcion represent a small percentage of the total number of patients who have used the drug."
Some of the side effects of Byetta can contribute to kidney problems. For example, diarrhea, nausea and vomiting can lead to dehydration. Patients are encouraged to ask their physicians about their kidney function before taking Byetta and to monitor for signs and symptoms while taking the drug. Symptoms of kidney disease include changes in urine color, swelling in the feet and legs, fatigue, nausea or vomiting, and dull ache in the mid to lower back. If left untreated, kidney damage can worsen and lead to kidney failure.
Kidney malfunction may also occur as a consequence of diabetes itself, other chronic conditions, such as pancreatitis and hypertension. Concomitant use of certain medications (nonsteroidal anti-inflammatory drugs, diuretics, and antihypertensives) can also lead to kidney problems. Discontinuation of Byetta should only be considered if kidney dysfunction cannot be explained by these or other causes.
The FDA is advising physicians to avoid prescribing Byetta for patients with severe renal impairment, identified as creatinine clearance less than 30 mL per minute, or end-stage renal disease. It also recommends using caution when initiating or increasing doses from 5 micrograms to 10 micrograms in patients with moderate renal impairment. Physicians should monitor patients for the development of kidney dysfunction while on Byetta.
In 2007, Byetta was linked to a higher risk of acute pancreatitis, a potentially life-threatening inflammation of the pancreas. In October 2007 and August 2008, the FDA issued safety alerts about the reports that included cases of hemorrhagic pancreatitis and nectrotizing pancreatitis, which can be fatal. The symptoms of pancreatitis include nausea, vomiting, severe abdominal pain, a rise or fall in blood pressure, and increase heart or respiratory rates.
Adverse events for any medication should be reported to the FDA's MedWatch Safety Information and Adverse Event Reporting Program.
Denise Reynolds RD LDN
Archive issues: (50)
Archive list: 1 [2] 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
December 12, 2009 | Researchers Find New Drug To Shrink Breast Cancer TumorsBoston (SmartAboutHealth) - Researchers have discovered a new antibody drug that has the ability to shrink breast cancer tumors that other drugs have failed to impact. The study was carried out by researcher Dr. Ian Krop and colleagues at the Dana Farber Cancer Institute. What they discovered is that a hybrid drug, T-DM1, was able to shrink or at least stop the growth of ...
December 11, 2009 | Fewer dollars for smoking preventionEven as states pull in billions of dollars in tobacco settlement money - part of which is typically used to fund anti-smoking programs - they're slashing the amount they spend on such programs by 15%. Altogether, states will spend $567.5 million on anti-smoking efforts in the 2010 fiscal year, says a report released by five groups including the Robert Wood Johnson Foundation and the Cancer Action Network. That’s less than a fifth of the nearly $3.7 ...
December 9, 2009 | Smoking Kills Millions Worldwide Every YearTobacco use kills at least 5 million people every year, a figure that could rise if countries don't take stronger measures to combat smoking, the World Health Organization said Wednesday. In ...
Related articles:
Nomenclature
Originally called interstitial cystitis, the name for this disorder changed to interstitial cystitis/painful bladder syndrome in the period 2002-2005. In 2007, the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) began using the umbrella term Urologic Chronic Pelvic Pain Syndromes (UCPPS) to refer to pain syndromes associated with the bladder (i.e. interstitial cystitis/painful bladder syndrome, IC/PBS) and the prostate gland (i.e. chronic prostatitis/chronic pelvic pain syndrome, CP/CPPS). In 2008, ...Section: Interstitial cystitis
Independence and invulnerability - coping strategies
Standards of masculinity can not only create stress in themselves for some men, they can also limit these men's abilities to relieve stress. Men and women have different ways that they appraise stressful situations and cope with them. Some men appraise situations using the schema of what is an acceptable masculine response rather than what is objectively the best response. Men are limited to a certain range of "approved" responses and coping strategies. Because of this limiting schema, ...Section: Mens health risks
Alprostadil
Alprostadil can be injected into the penis or inserted using a special applicator - usually just before sexual intercourse. Alprostadil has also become available in some countries as a topical cream (under the brand name Befar), and preliminary studies have shown a clinical efficacy of up to 83%. It has an onset of action of 10-15 minutes and its effects ...Section: Erectile Dysfunction